Serbian pulmonary disease research institute with expertise in smoking prevention and FAIR health data interoperability.
Institut za Plucne Bolesti Vojvodine (Institute for Pulmonary Diseases of Vojvodina) is a specialist clinical research centre in Serbia focused on respiratory medicine, lung disease diagnosis and treatment, and related public health challenges. In EU research, they have contributed as a clinical site providing patient data, disease-specific expertise, and real-world healthcare context — first in the area of smoking behaviour and cessation, then in health data infrastructure and interoperability. Their institutional focus on pulmonary conditions makes them a natural partner for research touching tobacco-related lung disease, chronic respiratory conditions, and clinical data governance. As a Serbian institution, they also bring a non-EU Balkan healthcare perspective that adds geographic and demographic diversity to pan-European health consortia.
Their institutional mission as a pulmonary disease institute underpins both projects — SmokeFreeBrain directly addresses smoking-related lung disease risk, and FAIR4Health drew on their clinical patient data assets.
SmokeFreeBrain (2015-2018) focused on multidisciplinary tools to improve public prevention measures against smoking, where IPBV contributed clinical and epidemiological expertise.
FAIR4Health (2018-2021) aimed to improve EU health research through FAIR data practices; IPBV contributed clinical datasets and participated in building interoperable health data infrastructure.
FAIR4Health keywords explicitly name health informatics and distributed data mining as core competencies exercised during that project.
In the first half of their H2020 participation, IPBV's EU research role was defined entirely by clinical domain knowledge — specifically smoking prevention and the public health burden of tobacco-related respiratory disease. By the time of FAIR4Health (2018-2021), their focus had shifted toward the infrastructure layer of health research: FAIR data principles, e-health services, health informatics, and distributed data mining. This suggests they evolved from being a clinical content contributor to also functioning as a data-providing and data-governance actor within larger digital health ecosystems. The trajectory is consistent with a clinical institution that accumulated structured patient data over time and then found value in contributing that data to EU-level interoperability efforts.
IPBV appears to be positioning itself as a clinical data contributor in digital health research networks, making them a relevant partner for future projects that need real-world pulmonary or respiratory patient data in an interoperable format.
IPBV has participated exclusively as a consortium member, never taking a coordinating role, which is typical for specialised clinical institutions whose primary contribution is domain expertise and patient data rather than project management. Both their projects were large Research and Innovation Actions, suggesting they are comfortable operating within sizeable multi-partner structures. With 32 unique partners across just two projects, they have broad but shallow network exposure — each project brought a new set of collaborators rather than a recurring core group.
IPBV has collaborated with 32 distinct organisations spanning 13 countries across two projects, indicating they have been embedded in large, geographically diverse consortia. Their network is wide relative to their project volume, but the absence of repeated partners suggests they have not yet built a settled inner circle of long-term collaborators.
IPBV is one of very few Serbian clinical institutions active in H2020 health research, giving them a distinct value as a non-EU Balkan clinical site — consortia benefit from this for geographic coverage requirements and for access to patient populations with different exposure and healthcare system profiles. Their combination of pulmonary clinical depth and demonstrated capacity for FAIR health data practices is relatively rare among specialist hospitals in the Western Balkans. For a consortium building around respiratory disease data or tobacco-related health outcomes across Europe, IPBV fills a specific niche that few Serbian research centres can.
